The Flow Cytometry Facility has supported UWCCC investigators since 1988. It includes laboratories at two sites. The main laboratory is located at the Clinical Science Center (CSC) and remodeling for a satellite laboratory that will be located on the central campus at the McArdle Laboratory will be completed in Fall 2006. The Facility is staffed from 8:00 AM until 5:00 PM Monday through Friday, but the technologies are available to trained users at all times. The laboratory staff maintain all instruments and provide support for data acquisition; sorting; instruction in performing data analysis, instruction on instrument operation, consultation on experimental design, sample handling, and staining protocols; education on basic principles of flow cytometry through seminars, lab meetings, or course work, as well as a series of three lectures for beginners offered monthly; on-site staining facilities; and sample preparation and analysis of specimens submitted from clinical trials. This service is also available to clinicians without research laboratories who are conducting clinical trials. (The facility is dedicated to research and does not perform routine clinical analyses used in patient diagnosis and treatment.) The Facility manages and operates the following equipment: two high-speed sorters, FACScan, FACSCalibur, LSR, Pathway Biolmager, off-line computers for data analysis, and an Olympus Fluorescence Microscope. Through support of the Cancer Center Support Grant coupled with a significant on-going investment by the Cancer Center with institutional funds and philanthropic funds, as well as support from successful instrumentation grants, this facility provides the latest cutting-edge technology to UWCCC members.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA014520-35
Application #
7726686
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2008-04-01
Budget End
2009-03-31
Support Year
35
Fiscal Year
2008
Total Cost
$216,894
Indirect Cost
Name
University of Wisconsin Madison
Department
Type
DUNS #
161202122
City
Madison
State
WI
Country
United States
Zip Code
53715
Liu, Bai; Jones, Monica; Kong, Lin et al. (2018) Evaluation of the biological activities of the IL-15 superagonist complex, ALT-803, following intravenous versus subcutaneous administration in murine models. Cytokine 107:105-112
Yu, Deyang; Yang, Shany E; Miller, Blake R et al. (2018) Short-term methionine deprivation improves metabolic health via sexually dimorphic, mTORC1-independent mechanisms. FASEB J 32:3471-3482
Carroll, Molly J; Fogg, Kaitlin C; Patel, Harin A et al. (2018) Alternatively-Activated Macrophages Upregulate Mesothelial Expression of P-Selectin to Enhance Adhesion of Ovarian Cancer Cells. Cancer Res 78:3560-3573
Ehlerding, Emily B; Grodzinski, Piotr; Cai, Weibo et al. (2018) Big Potential from Small Agents: Nanoparticles for Imaging-Based Companion Diagnostics. ACS Nano 12:2106-2121
Park, Linda; Schwei, R J; Xiong, P et al. (2018) Addressing Cultural Determinants of Health for Latino and Hmong Patients with Limited English Proficiency: Practical Strategies to Reduce Health Disparities. J Racial Ethn Health Disparities 5:536-544
Ehlerding, Emily B; Lan, Xiaoli; Cai, Weibo (2018) ""Albumin Hitchhiking"" with an Evans Blue Analog for Cancer Theranostics. Theranostics 8:812-814
Morris, Zachary S; Guy, Emily I; Werner, Lauryn R et al. (2018) Tumor-Specific Inhibition of In Situ Vaccination by Distant Untreated Tumor Sites. Cancer Immunol Res 6:825-834
Yu, Bo; Goel, Shreya; Ni, Dalong et al. (2018) Reassembly of 89 Zr-Labeled Cancer Cell Membranes into Multicompartment Membrane-Derived Liposomes for PET-Trackable Tumor-Targeted Theranostics. Adv Mater 30:e1704934
England, Christopher G; Jiang, Dawei; Ehlerding, Emily B et al. (2018) 89Zr-labeled nivolumab for imaging of T-cell infiltration in a humanized murine model of lung cancer. Eur J Nucl Med Mol Imaging 45:110-120
Rutter, Carolyn M; Kim, Jane J; Meester, Reinier G S et al. (2018) Effect of Time to Diagnostic Testing for Breast, Cervical, and Colorectal Cancer Screening Abnormalities on Screening Efficacy: A Modeling Study. Cancer Epidemiol Biomarkers Prev 27:158-164

Showing the most recent 10 out of 1528 publications